John what do you know about this two Flgr242 for muscle building Klotho for kidney disease Thank you

Precursors Explained Most people who spend money on NAD+ injections believe they are delivering NAD+ directly to their cells, and that the injection is more powerful than a pill because it skips digestion and goes straight into the bloodstream. The first part of that is true. The second part is where the logic breaks down. To understand why, you need a map of how NAD+ actually works in the body, because without that map, the argument for injections sounds perfectly reasonable. NAD+, which stands for nicotinamide adenine dinucleotide, is a molecule your cells use as a kind of electron shuttle, picking up and dropping off charged particles to power the energy production happening inside your mitochondria. Every cell in your body needs it constantly, and your total NAD+ supply turns over multiple times per day, meaning your body is continuously breaking it down and rebuilding it. The problem is that NAD+ is a large molecule, and large molecules cannot pass through cell membranes the way small ones can. The membrane is a selective barrier, and NAD+ does not have a direct transport mechanism that lets it cross intact into the interior of the cell where it is actually needed. This is where the injection story gets complicated. When you inject NAD+ into your bloodstream, the molecule circulates. But to get inside a cell and reach the mitochondria where it will be used, it cannot enter as NAD+. Instead, it gets broken down outside the cell into smaller components, specifically into something called nicotinamide, which is a simpler building block that cells can actually absorb. Once inside, the cell reconstructs NAD+ from that raw material through a series of enzymatic steps. The molecule you paid to inject was disassembled before it was used. What your cell actually worked with was the breakdown product, not the original compound. This is not a flaw in your biology. It is the system working correctly. Cells maintain tight control over what enters them, and they have sophisticated machinery for building NAD+ internally from precursors. The same machinery runs whether the precursor came from an injection, a supplement, or food.

Eli Lilly Just Sued Six Companies for Selling Retatrutide. Here Is What It Means for Access Going Forward Eli Lilly filed six federal lawsuits on August 12, 2026, against vendors selling retatrutide, and the choice of legal theory tells you almost everything you need to understand about what is actually happening here. Before getting into any of the specific legal mechanisms, here is the full picture: Lilly holds a patent on retatrutide that covers the molecule under any name, they are simultaneously fighting a separate case to get the compound classified in a legal category that would permanently block compounding pharmacies from ever making it, every current vendor is exposed to enforcement from multiple directions at once, and the lawsuits filed so far represent a fraction of the enforcement action already in motion. That is the map. Now here is what each piece of it means. The lawsuits are filed under false advertising law and against the distribution of an unapproved drug, not under patent law, and that distinction is worth sitting with for a moment. Patent infringement is the more obvious tool here, given that Lilly holds US Patent 11,542,313 B2 on this molecule since January 2023, covering the compound itself, the manufacturing processes, specific formulations, and methods of treatment. That patent does not expire until approximately January 2039, with continuation patents that can push coverage further. Lilly could have led with patent claims. They chose not to. The reason is optics and sequencing. When a pharmaceutical company sues for patent infringement, the narrative that emerges is a corporation protecting its revenue. When the same company sues for false advertising and distribution of an unapproved drug, the narrative is a corporation protecting consumers from unsafe, unverified products. Lilly's legal team made a deliberate choice to enter this fight framed as a safety issue rather than a commercial one, and that framing matters for how regulators, courts, and the public receive the cases.

Got notified this morning that my channel has been deleted by YouTube. Onward and upward my friends. I’m Rethinking things and figuring out next steps. This will not change anything here or on the podcast platforms. The reality is that the topic of peptides is a very controversial subject and more is coming for the majority of content creators very soon. My goal is and has always been to provide the data in a clear concise package. I will continue to do just that moving forward regardless of restrictions, suspensions or cancellations. Stay tuned

I need 2 volunteers to check out something with me. (peptide related of course…not an actual peptide, but in relation to them) Any takers?